Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
Aerie plans to initiate the last of the trials, the COMET-4 safety study, in the fourth quarter of 2022.
- Aerie plans to initiate the last of the trials, the COMET-4 safety study, in the fourth quarter of 2022.
- Study participants will be randomized in a 1:1 ratio to receive either AR-15512 (0.003%) or AR-15512 vehicle as a drop dosed twice daily in each eye for three months.
- Participants will be evaluated on multiple efficacy and safety assessments at multiple timepoints throughout the study.
- Aerie is delighted to have enrolled the first participant in the COMET-3 study, said Michelle Senchyna, Ph.D., Head of Clinical Development and Medical Affairs at Aerie.